🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application

Month: September 2022

Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date

ATMA’s N500 Phase II Clinical Trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB, Sept. 14, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company …

Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date Read More »

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants

Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin  – Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, …

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants Read More »